Adrafinil for Health & Longevity

Evidence Review created on 09/28/2026 using AI4L / Opus 5.5

Also known as: Olmifon, CRL-40028, N-hydroxymodafinil

Motivation

Adrafinil (Olmifon) is a synthetic wakefulness-promoting compound that the liver converts into modafinil, a prescription medication for excessive sleepiness. It attracts health-focused adults who want steadier alertness, sharper attention and sustained mental output, partly because in several countries it can be bought online without a prescription.

Adrafinil was developed in France in the 1970s and prescribed there for decades to older adults with slowed thinking and reduced alertness, until its manufacturer stopped selling it in 2011. Since then it has circulated mainly as an online product marketed for mental performance, outside pharmaceutical quality control. Most of what is said about it is drawn from research on modafinil rather than from studies of adrafinil itself, which is what makes a careful look at the evidence worthwhile.

This review examines what is known about adrafinil’s effects on alertness and thinking, the risks it carries, how it has been taken, and how the gap between adrafinil and modafinil research shapes what can be concluded.

Benefits - Risks - Protocol - Conclusion

Recommended Reading

The items below give high-level overviews of adrafinil and of modafinil, the active compound adrafinil becomes in the body.

• Modafinil - Gwern Branwen

  Long-form essay on modafinil’s cognitive effects, side effects, tolerance and legal status that discusses adrafinil by name as its liver-activated prodrug (inactive precursor) and explains why users moved to modafinil.

• Adderall, Stimulants & Modafinil for ADHD: Short- & Long-Term Effects - Andrew Huberman

  Explains the brain circuits of focus in attention-deficit/hyperactivity disorder (ADHD), with a dedicated segment on modafinil, the compound adrafinil becomes: its uses against daytime sleepiness and its side effects, including a rare, severe skin reaction.

• Modafinil: its discovery, the early European and North American experience in the treatment of narcolepsy and idiopathic hypersomnia, and its subsequent use in other medical conditions - Billiard & Broughton, 2018

  Firsthand history of how adrafinil’s stimulant effect in mice led to early use in narcolepsy (sudden sleep attacks) and idiopathic hypersomnia (unexplained excessive sleepiness), and to modafinil’s discovery as its active metabolite (breakdown product).

• Pharmacokinetic and pharmacodynamic of the cognitive enhancer modafinil: Relevant clinical and forensic aspects - Sousa & Dinis-Oliveira, 2020

  Narrative review of modafinil and its prodrug adrafinil covering absorption, liver metabolism, brain targets, common and severe side effects, and misuse, clarifying what adrafinil ultimately delivers.

• Adrafinil: effects on behavior and cognition in aged canines - Siwak et al., 2000

  Summary of the aged-dog research program in which adrafinil raised activity, brain-wave arousal and learning; two authors are inventors on the veterinary company Vétoquinol’s patent for adrafinil in aged dogs.

Among the priority experts, only Andrew Huberman has directly relevant content (a dedicated modafinil segment). Peter Attia and Chris Kresser mention modafinil only in passing within episodes on other topics, Rhonda Patrick discusses modafinil only as one topic of a wide-ranging 2015 guest interview on the Optimal Performance Podcast and within broad FoundMyFitness stimulant episodes featuring Andrew Huberman, Life Extension Magazine names adrafinil only in passing within a 2005 book review, and no other priority expert or Lifespan.io has content naming adrafinil, likely because it is a discontinued French drug rather than a mainstream longevity supplement.

Grokipedia

Adrafinil

Broad overview of adrafinil’s chemistry, conversion to modafinil, French clinical history, dog studies and safety; some claims, such as liver injury driving the 2011 withdrawal, lack verifiable primary sources.

Examine

No Examine article on adrafinil exists. Adrafinil was a prescription medication in France and is an unapproved drug elsewhere; Examine.com does not typically cover prescription or unapproved pharmaceutical drugs.

ConsumerLab

No ConsumerLab article on adrafinil exists; the site search returns only a 2019 recall-and-warning notice about supplements marketed for dementia, not a review of adrafinil. ConsumerLab does not typically cover prescription or unapproved pharmaceutical drugs.

Systematic Reviews

No systematic reviews or meta-analyses for Adrafinil were found on PubMed as of 09/28/2026.

Neither the claimed alertness and cognitive effects nor the principal risks of adrafinil are represented by a systematic review; reviews of modafinil, the compound adrafinil becomes in the body, are cited within the Benefits and Risks sections instead.

Mechanism of Action

Adrafinil is a prodrug (an inactive compound the body converts into an active drug). After oral intake the liver converts it into modafinil, a eugeroic (wakefulness-promoting agent), and into inactive modafinil acid; the enzymes performing this step are not well characterized.

• Primary action: modafinil weakly blocks the dopamine transporter (DAT, the protein that clears dopamine from the gap between nerve cells), raising dopamine in the brain’s reward and motivation hubs (Volkow et al., 2009). Its direct binding to noradrenaline and serotonin transporters and to most receptors is weak, making it relatively selective for the dopamine transporter.
• Downstream arousal systems: it indirectly raises noradrenaline, histamine, orexin (a wake-sustaining brain signal) and glutamate while lowering GABA (gamma-aminobutyric acid, the brain’s main calming messenger) (Hersey & Tanda, 2024).
• Competing explanation: early work by the manufacturer’s own Laboratoire L. Lafon scientists attributed adrafinil’s stimulation to α1-adrenergic receptors (noradrenaline receptors that heighten arousal), because blocking them prevented hyperactivity in mice (Duteil et al., 1979); later human imaging favors the dopamine-transporter explanation, and both may contribute.
• Pharmacology: adrafinil’s own half-life (time for blood levels to fall by half) is about one hour; modafinil’s is 12–15 hours. Modafinil distributes widely into body tissues, including the brain, is cleared mainly by amide hydrolysis (enzymatic splitting) with a smaller CYP3A4 (a major drug-clearing liver and gut enzyme) contribution, modestly induces CYP3A4 and inhibits CYP2C19 (a liver enzyme clearing some sedatives and anticonvulsants) (Robertson & Hellriegel, 2003). Those authors were employees of Cephalon, modafinil’s manufacturer.

Historical Context & Evolution

Adrafinil was synthesized in 1974 by Laboratoires Lafon in France during a search for pain-relieving compounds. In mice, according to Lafon’s own researchers, it increased motor activity without peripheral stimulant signs such as pupil dilation (Rambert et al., 1986). The sleep researcher Michel Jouvet prescribed it to narcolepsy patients in 1977–78 with inconsistent results; studies of how the body processes it then identified modafinil as the active metabolite, which was registered in France in 1992 and later in the United States (Billiard & Broughton, 2018).

Adrafinil itself was marketed in France from 1985 as Olmifon for reduced vigilance, attention and slowed thinking in older adults, framed around the role of noradrenaline in brain aging (Jouvet et al., 1991). The supporting human studies were small, French-language and largely unindexed; their reported gains were neither replicated nor refuted by modern trials. In the late 1990s, Canadian researchers working with the veterinary company Vétoquinol tested it in aged dogs as a model of cognitive aging (Siwak et al., 2000).

The manufacturer, by then Cephalon, discontinued Olmifon in September 2011, a decision Grokipedia’s adrafinil article attributes to an unfavorable benefit–risk ratio; no detailed rationale was published. Modafinil’s own approval had already made the prodrug commercially redundant, and no published study documents new safety findings behind the decision. The World Anti-Doping Agency has banned adrafinil in sport since 2004, and since 2011 it has been sold online as an unregulated cognitive-enhancement product.

Expected Benefits

High 🟩 🟩 🟩

No benefit reaches High: no controlled human trial of adrafinil itself is indexed on PubMed, and the replicated randomized trials concern modafinil, which is indirect evidence for adrafinil.

Medium 🟩 🟩

No benefit reaches Medium: adrafinil’s own human data are small, uncontrolled or unindexed French clinical series, and no single indexed randomized trial of adrafinil exists.

Low 🟩

Alertness During Sleep Loss, Night Work and Sleep Disorders

Modafinil, adrafinil’s active form, reduced sleepiness in randomized trials of sleep-deprived adults, night-shift workers (Czeisler et al., 2005), narcolepsy (US Modafinil in Narcolepsy Multicenter Study Group, 1998) and sleep apnea (breathing pauses during sleep) (Pack et al., 2001). The last three were manufacturer-funded; no adrafinil trial exists.

Magnitude: In shift-work sleep disorder (sleepiness and insomnia caused by night work), modafinil 200 mg improved clinical symptoms in 74% versus 36% on placebo and reduced commuting near-accidents (29% versus 54%); in sleep apnea despite continuous positive airway pressure therapy (a bedside breathing device), 51% versus 27% reached a normal Epworth Sleepiness Scale score (below 10 on a validated sleepiness questionnaire); after 41.5 hours awake, 200–400 mg matched 600 mg caffeine (Wesensten et al., 2002).

Cognitive Performance in Rested Adults ⚠️ Conflicted

A meta-analysis of 14 modafinil studies found a small effect, largest for memory updating (Roberts et al., 2020). A systematic review found complex-task gains but inconsistent simple-test results, and some studies reported impaired creative thinking (Battleday & Brem, 2015). Adrafinil is untested. Net reading: a small, task-specific effect.

Magnitude: Overall standardized mean difference (SMD, effect size in standard-deviation units, where 0.2 is conventionally small) 0.12 for modafinil versus placebo, and 0.28 for memory updating.

Mood and Fatigue as Add-On in Depression ⭕️ Not Central to Health & Longevity

Added to antidepressants, modafinil improved depression scores, remission and fatigue in a meta-analysis of six randomized trials with 910 patients (Goss et al., 2013). This bears on treating depressive episodes, not on healthy aging. No adrafinil trials exist.

Magnitude: Depression-score effect −0.35 (95% confidence interval, CI, the range likely to contain the true value, −0.61 to −0.10); odds ratio (OR, relative odds versus placebo) for remission 1.61.

Age-Related Mental Slowing

French authors framed adrafinil, licensed for slowed thinking in older adults, around noradrenaline’s role in brain aging (Jouvet et al., 1991). Its small, unindexed human studies are known secondhand (Siwak et al., 2003). Aged-dog learning gains (Milgram et al., 2000) come from Vétoquinol patent holders. No modern controlled trial exists.

Magnitude: Not quantified in available studies. The French trials in older adults are unindexed and report no extractable outcome figures, and the only indexed data come from aged dogs.

Speculative 🟨

Protection of the Aging Brain

Early French authors proposed that strengthening noradrenaline signaling with adrafinil might protect aging brains (Jouvet et al., 1991). The basis is mechanistic reasoning only; no human outcome data exist.

Benefit-Modifying Factors

• Genetic polymorphisms: Under sleep deprivation, modafinil maintained vigor, executive function (planning and mental control) and attention in people with the COMT (catechol-O-methyltransferase, an enzyme that breaks down prefrontal dopamine) Val/Val genotype but was hardly effective in Met/Met carriers (Bodenmann et al., 2009).
• Baseline sleep debt: Benefits are largest when sleep-deprived; in rested people modafinil mainly improved attention, while in sleep-deprived people it preserved wakefulness, memory and executive function (Repantis et al., 2010).
• Baseline liver function: Adrafinil needs liver conversion to act; reduced liver function may delay or blunt modafinil formation while slowing its clearance, making effects less predictable (Robertson & Hellriegel, 2003).
• Sex: No sex-specific difference in benefit is established; much mechanistic work, including dopamine imaging, studied men only (Volkow et al., 2009).
• Pre-existing conditions: People with depression-related fatigue or night-shift sleepiness show clearer benefit than healthy, rested adults; untreated sleep apnea or other sleep disorders can be masked rather than resolved.
• Age: Older adults were adrafinil’s original target group; slower modafinil clearance in aging prolongs effects, but modern controlled data at the older end of the range are absent.

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: adrafinil has no indexed controlled human trials, and the replicated adverse-event data come from modafinil trials, which are indirect evidence for adrafinil.

Medium 🟥 🟥

No risk reaches Medium: adrafinil-specific human harm data consist of a single case report and forensic analyses, and modafinil trial data remain indirect.

Low 🟥

Insomnia and Disrupted Sleep

Modafinil’s 12–15-hour half-life keeps the brain alert at bedtime when doses are taken late; adrafinil’s slower onset pushes exposure later still. Reviews of randomized modafinil trials list insomnia among common adverse events (Kumar, 2008).

Magnitude: Insomnia in 5% of modafinil-treated versus 1% of placebo patients in pooled trials used for its US approval (modafinil prescribing information); adrafinil-specific rates are not reported.

Headache, Nausea and Nervousness

Headache was the most common adverse event in a three-month modafinil trial in night workers (Czeisler et al., 2005); nausea, nervousness and anxiety follow. Headache and anxiety are dose-related. Adrafinil delivers modafinil, so similar effects are expected, though equivalent dosing is unmeasured.

Magnitude: In pooled modafinil trials, headache 34% versus 23% on placebo, nausea 11% versus 3%, nervousness 7% versus 3%, anxiety 5% versus 1% (modafinil prescribing information).

Raised Blood Pressure, Heart Rate and Cardiac Strain

Modafinil can raise blood pressure and heart rate; a drug-safety case report described treatment-resistant hypertension (Amar et al., 2013). Trial participants with mitral valve prolapse (a floppy heart valve) or left ventricular hypertrophy (thickened heart muscle) developed chest pain, palpitations and electrocardiogram signs of reduced blood flow (modafinil prescribing information).

Magnitude: In the trials used for its US approval, 2.4% of modafinil-treated versus 0.7% of placebo patients needed new or increased blood-pressure medication; chest pain occurred in 3% versus 1%, and palpitations and fast heart rate each in 2% versus 1% (modafinil prescribing information).

Liver Enzyme Elevation

Adrafinil depends on conversion in the liver, adding liver workload, and modafinil is itself cleared by the liver (Robertson & Hellriegel, 2003). Modafinil trials showed rising mean liver enzymes. Claims of progressive adrafinil liver damage lack published human cases.

Magnitude: In pooled modafinil trials, “abnormal liver function” occurred in 2% versus 1% on placebo, with mean gamma-glutamyl transferase (GGT) and alkaline phosphatase (liver enzymes whose blood levels rise with liver stress or impaired bile flow) rising but rarely leaving the normal range (modafinil prescribing information).

Serious Skin and Hypersensitivity Reactions

Modafinil can trigger rare, potentially fatal Stevens-Johnson syndrome (blistering of skin and mucous membranes) (Prince et al., 2018). Case reports also describe DRESS (drug reaction with eosinophilia and systemic symptoms, a multi-organ allergic reaction) (Kasitinon et al., 2022). Most cases begin within five weeks.

Magnitude: Rash leading to discontinuation occurred in 0.8% (13 of 1,585) of pediatric modafinil trial patients; adult severe reactions are rare, with reporting rates above the background of 1–2 per million person-years (cases per million people followed for one year) (modafinil prescribing information).

Psychiatric Reactions

Case reports link modafinil to mania (abnormally elevated mood and energy), agitation and suicidal thoughts, including psychosis (loss of contact with reality) at 100 mg/day in a previously healthy student (Aytaş & Dilek Yalvaç, 2015). Risk appears higher with psychiatric history, high doses and sleep loss.

Magnitude: In controlled modafinil trials, confusion, agitation and depression each caused discontinuation in under 1% of patients; mania and psychosis appear only in post-marketing reports without incidence figures (modafinil prescribing information).

Dependence and Misuse Potential

Modafinil blocks dopamine transporters and raises dopamine in the brain’s reward hub, a property shared with addictive stimulants (Volkow et al., 2009). Documented dependence is uncommon, but tolerance and escalating use are reported.

Magnitude: In people experienced with drugs of abuse, modafinil 200–800 mg produced euphoric, methylphenidate-like effects (modafinil prescribing information); the literature reports no dependence incidence figure.

Involuntary Facial Movements

A French case described orofacial dyskinesia (involuntary mouth and face movements) after adrafinil that persisted four months after stopping and responded to tetrabenazine, a dopamine-depleting drug (Thobois et al., 2004). It is the only adrafinil-specific adverse-event case indexed on PubMed.

Magnitude: Dyskinesia was reported in 1% of modafinil-treated versus 0% of placebo patients in pooled trials (modafinil prescribing information); no adrafinil incidence figure exists.

Pregnancy-Related Adverse Outcomes

A modafinil pharmacovigilance (drug-safety reporting) study found reporting signals for spontaneous abortion, premature labor and neonatal disorders not listed on its label (Zhang et al., 2026). Modafinil also weakens hormonal contraception. No adrafinil pregnancy data exist.

Magnitude: Disproportionate reporting of pregnancy-related events appeared among 3,070 modafinil adverse-event reports (2004–2024); the literature reports no incidence figure from controlled data.

Speculative 🟨

Working Memory Impairment at Higher Doses

In aged beagles, 20 mg/kg adrafinil increased errors on a spatial working-memory task (Siwak et al., 2003). Evidence is animal-only; no human outcome data exist, and relevance to human doses is unknown.

Risk-Modifying Factors

• Genetic polymorphisms: CYP2D6 poor metabolizers (people with minimal activity of this antidepressant-clearing liver enzyme) taking tricyclic or SSRI (selective serotonin reuptake inhibitor) antidepressants face higher drug levels, because clearance then shifts to CYP2C19, which modafinil inhibits (modafinil prescribing information).
• Baseline liver enzymes: Pre-existing elevation of ALT (alanine aminotransferase), AST (aspartate aminotransferase) or GGT (gamma-glutamyl transferase), all liver-injury markers, signals reduced reserve for a compound requiring liver conversion.
• Baseline blood pressure: Readings at or above 130/80 mmHg raise the consequence of modafinil-related blood-pressure increases, which were larger in sleep apnea populations.
• Sex: Women using hormonal contraception face contraceptive failure through CYP3A4 induction; pregnancy-related signals make this sex-specific risk important. Sex differences in other adverse-event rates are not established.
• Pre-existing conditions: Psychosis, bipolar disorder, anxiety disorders, arrhythmia (irregular heartbeat), left ventricular hypertrophy (thickened heart muscle), liver disease and severe kidney impairment, where modafinil acid accumulates, raise risk (Kumar, 2008).
• Age: Older adults clear modafinil more slowly, prolonging exposure and sleep disruption; the modafinil prescribing information advises lower doses and closer monitoring in geriatric patients.

Key Interactions & Contraindications

• Hormonal contraceptives (ethinyl estradiol oral contraceptives, patches, rings): Caution. Modafinil induces CYP3A4, lowering contraceptive levels and risking unintended pregnancy, per a Cephalon-run study (Robertson et al., 2002). Mitigation: non-hormonal or additional contraception during use and for one month after.
• CYP3A4-cleared drugs (triazolam, midazolam, cyclosporine): Monitor. Reduced blood levels may cause loss of effect, including transplant-rejection risk with cyclosporine. Mitigation: drug-level monitoring and dose adjustment.
• CYP2C19-cleared drugs (diazepam, phenytoin, omeprazole, clomipramine): Monitor. Raised levels may cause sedation or toxicity. Mitigation: lower doses of the affected drug and clinical monitoring.
• Warfarin (a blood thinner): Monitor. Modafinil suppresses CYP2C9 (warfarin’s main clearing liver enzyme) in liver-cell studies (Robertson & Hellriegel, 2003), which may shift clotting control. Mitigation: more frequent INR (international normalized ratio, a clotting-time test) checks during use.
• Monoamine oxidase inhibitors (phenelzine, tranylcypromine, selegiline): Caution. These antidepressants (which block noradrenaline and dopamine breakdown) add stimulation and blood-pressure elevation. Mitigation: combination only under physician supervision.
• Prescription stimulants (amphetamine, methylphenidate): Caution. Additive rises in heart rate, blood pressure, anxiety and insomnia. Mitigation: no same-day use.
• Antihypertensives (amlodipine, lisinopril, losartan): Monitor. Modafinil can blunt the control these drugs (blood-pressure-lowering medications) provide. Mitigation: home blood-pressure checks during the first month.
• Over-the-counter decongestants (pseudoephedrine, phenylephrine) and caffeine products: Caution. Additive stimulation, palpitations, insomnia and blood-pressure rise. Mitigation: caffeine limited to one to two cups and no decongestants on dosing days.
• Acetaminophen (paracetamol): Monitor. Theoretical additive liver workload during prolonged use. Mitigation: acetaminophen kept under 3 g/day, with liver-enzyme checks.
• Alcohol: Caution. Alcohol adds liver burden, and wakefulness can mask intoxication. Mitigation: no alcohol on dosing days.
• Stimulant supplements (yohimbine, synephrine or bitter orange, high-dose caffeine): Caution. Additive heart-rate and blood-pressure effects; adrafinil potentiated yohimbine toxicity in mice (Rambert et al., 1986). Mitigation: no concurrent use.
• St. John’s wort: Monitor. As a CYP3A4 inducer it may shorten modafinil’s action and compounds contraceptive failure. Mitigation: no concurrent use with hormonal contraception.
• Liver-burdening supplements (kava, high-dose green tea extract): Caution. Potential additive liver stress. Mitigation: no concurrent use, plus liver-enzyme monitoring.
• Driving after sleep loss (other intervention): Caution. Modafinil-treated night workers remained excessively sleepy and impaired (Czeisler et al., 2005). Mitigation: adrafinil is not a substitute for sleep before driving.

Populations who should avoid Adrafinil:

• Pregnant or breastfeeding women, and women relying solely on hormonal contraception
• People with liver disease (e.g., cirrhosis of Child-Pugh Class B or C, a liver-severity score, or ALT above three times the upper limit of normal)
• People with uncontrolled hypertension (≥160/100 mmHg), recent heart attack (<90 days), unstable angina (chest pain at rest), significant arrhythmia, left ventricular hypertrophy, or mitral valve prolapse (a floppy heart valve) with prior stimulant-related chest pain or arrhythmia
• People with a history of psychosis, bipolar disorder or mania, or a severe anxiety disorder
• People with severe kidney impairment (estimated glomerular filtration rate, eGFR, a measure of how well the kidneys filter blood, <30 mL/min/1.73 m²)
• Anyone with a prior serious rash or hypersensitivity reaction to modafinil or armodafinil
• Competitive athletes subject to anti-doping testing
• Children and adolescents under 18 years

Risk Mitigation Strategies

• Baseline and follow-up liver panel: ALT, AST, GGT and bilirubin checked before starting, at 4–8 weeks, then every 3 months, with stopping if ALT exceeds three times normal. Mitigates undetected liver enzyme elevation.
• Morning-only dosing: A last dose before noon mitigates insomnia and disrupted sleep from modafinil’s 12–15-hour half-life.
• Low starting dose: Starting at 150 mg and moving to 300 mg only after 3–5 well-tolerated uses mitigates dose-related headache, nausea and anxiety.
• Blood-pressure tracking: Weekly blood pressure and resting heart rate in the first month, stopping if readings stay above 140/90 mmHg, mitigates hypertension and palpitations.
• Stop at first rash: Discontinuation at any rash, mouth sores, fever or facial swelling, especially in weeks 1–5, mitigates progression to Stevens-Johnson syndrome or DRESS.
• Intermittent use: Use limited to 2–3 days per week mitigates tolerance, escalating use and cumulative liver exposure.
• Backup contraception: Non-hormonal contraception during use and for one month after mitigates contraceptive failure and pregnancy exposure.
• Psychiatric screening: Excluding people with psychosis or mania history, and stopping at agitation, paranoia or mood elevation, mitigates psychiatric reactions.
• Verified sourcing: Batches with an independent certificate of analysis confirming identity and content mitigate mislabeled doses that would amplify the dose-related headache, anxiety and insomnia described under Risks.

Therapeutic Protocol

• Historical French protocol (Olmifon): 600–1,200 mg/day (two to four 300 mg tablets), split morning and midday, for older adults with reduced vigilance; the regimen of Laboratoires Lafon’s label and French geriatric practice.
• Online nootropic (cognition-enhancer) protocol: 150–300 mg once in the morning on an empty stomach, used intermittently; popularized by nootropic communities and writers such as Gwern Branwen. A 3:1 adrafinil-to-modafinil milligram ratio is a community estimate, not a measured equivalence.
• Prescribed modafinil alternative: Sleep physicians prescribe modafinil 100–200 mg directly, avoiding the prodrug’s liver conversion step; this requires a prescription and a qualifying indication in most countries.
• Caffeine alternative: During sleep deprivation, 600 mg caffeine matched modafinil 200–400 mg (Wesensten et al., 2002), making caffeine a comparator for situational alertness.
• Time of day: Early morning, ideally on waking; effects begin 45–60 minutes later on an empty stomach. Doses after noon risk disrupted sleep.
• Half-life: Adrafinil itself has a half-life of about one hour; the modafinil it forms has 12–15 hours and reaches stable blood levels after 2–4 days of daily dosing (Robertson & Hellriegel, 2003).
• Single versus split dose: Doses up to 300 mg are taken once in the morning; the historical 600–1,200 mg regimen was split into morning and midday doses.
• Genetic polymorphisms: COMT Val/Val carriers responded more strongly than Met/Met carriers at one modafinil dose (Bodenmann et al., 2009); CYP2D6 poor metabolizers taking tricyclic or SSRI antidepressants may need lower antidepressant doses. No genotype-guided adrafinil dosing is validated.
• Sex-based differences: No sex-specific dose exists; the modafinil prescribing information’s contraception interaction applies at every dose and specifies alternative or additional non-hormonal methods during use and for one month after.
• Age: Older adults, adrafinil’s original population, clear modafinil more slowly; starting at 150 mg reflects the modafinil prescribing information’s advice to use lower doses in geriatric patients.
• Baseline biomarkers: Normal liver enzymes and blood pressure below 130/80 mmHg before starting; abnormal values argue against unsupervised use.
• Pre-existing conditions: Adrafinil can mask untreated sleep apnea, a common cause of unexplained daytime sleepiness; psychiatric, cardiac, liver or kidney disease raises the risk of adverse effects and appears among the populations who should avoid it.

Discontinuation & Cycling

• Short-term, situational use: Adrafinil is used for specific demanding days or periods, not as lifelong therapy; no long-term safety data support continuous use.
• Withdrawal effects: No classic withdrawal syndrome is described; rebound fatigue and sleepiness can follow stopping after daily use.
• Tapering: Abrupt stopping is generally acceptable; daily users at 600 mg or more may halve the dose for 3–5 days to soften rebound fatigue.
• Cycling: Communities commonly use 2–3 days per week or alternate 1–2 weeks on and off to limit tolerance and liver exposure; this pattern is anecdotal, and aged dogs showed no tolerance over 14 days (Siwak et al., 2000).
• Immediate stop signals: Rash, yellowing skin or eyes, dark urine, chest pain, palpitations, or new agitation or paranoia are early signs of the serious reactions listed under Risks; the modafinil prescribing information specifies discontinuation at the first rash.

Sourcing and Quality

• No pharmaceutical-grade source: Olmifon was discontinued in 2011, so all adrafinil now comes from unregulated chemical or supplement vendors without pharmaceutical manufacturing oversight.
• Supplement status: A US Food and Drug Administration (FDA) laboratory found adrafinil in all four products labeled to contain it and treats it as an unapproved active pharmaceutical ingredient, not a dietary ingredient (Bakota & Nandrea, 2025).
• What to look for: A batch-specific certificate of analysis from an independent laboratory confirming identity and purity (≥98% by a standard laboratory purity test), plus heavy-metal, residual-solvent and microbial testing.
• Analog substitution: Vendors also sell untested analogs such as CRL-40,940 and CRL-40,941 (fladrafinil); confirming the exact compound matters because these have no human safety data.
• Formulation: Capsules give more reliable dosing than bulk powder, which requires a milligram-accurate scale; the powder is poorly water-soluble and bitter.
• Reputable brands and pharmacies: No brand has public, independently verified testing, so none is named; US compounding pharmacies generally cannot use adrafinil because it is neither an approved drug nor a listed bulk substance.

Practical Considerations

• Time to effect: Alertness effects appear 45–60 minutes after an empty-stomach dose, later than modafinil, and last most of the day; no cumulative benefit with repeated use has been shown.
• Common pitfalls: Dosing after noon, combining it with high caffeine intake, treating adrafinil as a substitute for sleep, skipping liver monitoring, and buying powder without a certificate of analysis.
• Regulatory status: Neither FDA-approved nor federally scheduled in the United States, unlike Schedule IV (low-tier controlled) modafinil; prescription-only in Australia; no longer marketed in France; banned in competition by the World Anti-Doping Agency since 2004 (Ameline et al., 2020).
• Anti-doping detection: Adrafinil and its metabolites modafinil and modafinil acid are detectable in urine with standard doping-control methods (Lu et al., 2009).
• Structural bias in research funding: Because adrafinil is off-patent and unreimbursed, no manufacturer, insurer or health system has an incentive to fund trials, while modafinil’s approved, reimbursed status channeled research toward it; this explains much of the missing adrafinil data.
• Cost and accessibility: Cost is low, but access is limited to unregulated online vendors of variable quality.

Interaction with Foundational Habits

• Sleep: Blunting. Modafinil’s 12–15-hour half-life delays sleep onset and shortens sleep when dosed late. It does not remove the need for recovery sleep and can create overconfidence in performance during sleep loss (Repantis et al., 2010). Practical: dosing on waking and protecting a full sleep window limit this.
• Nutrition: Indirect. An empty stomach speeds onset, while food delays it. Modafinil reduces appetite (appetite loss in 4% versus 1% on placebo, per the modafinil prescribing information), which can undercut protein and calorie targets. No specific nutrient depletion is known. Practical: planned meals offset reduced hunger, and alcohol on dosing days adds liver workload.
• Exercise: Potentiating with caution. Modafinil raises heart rate and blood pressure and may reduce perceived effort, so training intensity can exceed usual limits. Practical: dosing right before maximal or hot-weather sessions adds cardiovascular strain, and competitive athletes face anti-doping prohibition.
• Stress management: Direct. Raised noradrenaline and dopamine can amplify anxiety and nervousness (anxiety 5% versus 1% on placebo, per the modafinil prescribing information), especially under sleep loss. Practical: anxiety-prone users fare worse on high-stress days, and established practices such as slow breathing can offset nervousness.

Monitoring Protocol & Defining Success

Before starting, baseline testing establishes reference values: a liver panel, kidney function, blood pressure and resting heart rate, and a pregnancy test where relevant. People with psychiatric or cardiac history, or abnormal baseline results, are poor candidates for unsupervised use.

Ongoing monitoring follows a fixed cadence: liver enzymes at 4–8 weeks, then every 3 months while use continues; blood pressure and resting heart rate weekly during the first month, then monthly; and sleep, mood and focus reviewed at 2 weeks and at each later check. Success means clearer alertness on dosing days without worsening sleep, blood pressure, mood or liver markers. A rise in liver enzymes, sustained blood pressure above 140/90 mmHg, or any rash or psychiatric change marks failure of tolerability regardless of perceived benefit.

Biomarker	Optimal Functional Range	Why Measure It?	Context/Notes
ALT	<25 U/L	Liver-cell injury	Alanine aminotransferase; conventional upper limit about 40–55 U/L; no fasting needed; avoid hard exercise 48 hours before
AST	<25 U/L	Liver and muscle injury	Aspartate aminotransferase; conventional upper limit about 40 U/L; pair with ALT, since intense exercise raises AST alone
GGT	<25 U/L	Liver enzyme induction	Gamma-glutamyl transferase; conventional upper limit about 60 U/L; modafinil can raise mean GGT, so trend matters more than one value
Alkaline phosphatase	40–100 U/L	Bile-flow and liver stress	Conventional range about 40–130 U/L; modafinil raised mean values in trials
Total bilirubin	0.3–1.0 mg/dL	Liver clearance function	Conventional upper limit 1.2 mg/dL; rising bilirubin with ALT elevation signals clinically important liver injury
eGFR	>90 mL/min/1.73 m²	Kidney clearance of metabolites	Estimated glomerular filtration rate; conventional normal >60; modafinil acid accumulates below 30
Blood pressure	<120/80 mmHg	Stimulant blood-pressure rise	Conventional hypertension threshold 130/80 mmHg; measure seated, same time of day, 2–3 hours after dosing
Resting heart rate	50–70 bpm	Stimulant cardiac effect	Beats per minute; conventional range 60–100; measure on waking and 2–3 hours after dosing
Pregnancy test (where relevant)	Negative	Avoid fetal exposure	Human chorionic gonadotropin test; required before use in women who could become pregnant

Qualitative markers:

• Daytime alertness: Epworth Sleepiness Scale score (a validated eight-item sleepiness questionnaire) compared with baseline
• Focus and task completion: Self-rated concentration and output on demanding days
• Sleep quality: Sleep-onset time, total sleep and morning refreshment, tracked by diary or wearable
• Mood and anxiety: Irritability, nervousness or mood elevation on dosing days
• Appetite and headache: Frequency of skipped meals and headaches

Emerging Research

• No registered adrafinil trials: A ClinicalTrials.gov search in September 2026 found no interventional adrafinil trial; human evidence for health-focused users will continue to come from modafinil studies.
• Modafinil under combined cold and sleep loss: NCT07830056 is a recruiting Phase 4 trial (33 participants) of modafinil 200 mg versus placebo measuring vigilance, working memory and body heat, which could strengthen or weaken alertness claims under real-world stressors.
• Modafinil plus exercise for fatigue after stroke: NCT06354985 is a Phase 3 trial (212 participants, not yet recruiting) combining modafinil 200 mg with home exercise, with fatigue severity as the primary endpoint.
• Noradrenaline-center imaging: NCT06041048 is a recruiting Phase 4 study (40 healthy adults) using modafinil to probe the locus coeruleus, the brainstem noradrenaline center, which could clarify the competing mechanistic explanations.
• Cognition in multiple sclerosis: NCT06592352 is an open-label (unblinded, no placebo) Phase 2 trial (64 participants) testing modafinil for cognitive deficits and using functional magnetic resonance imaging (brain-activity scanning) to identify responders.
• New safety signals: A 2026 analysis of the FDA Adverse Event Reporting System identified pregnancy-related and cardiac signals absent from modafinil’s label (Zhang et al., 2026), which could weaken the safety case for adrafinil.
• Small effects in rested adults: Meta-analytic evidence that modafinil’s cognitive gains in rested adults are small (Roberts et al., 2020) sets a ceiling future adrafinil claims must exceed.
• Supplement surveillance: FDA laboratory methods now detect adrafinil and newer analogs in products marketed as supplements (Bakota & Nandrea, 2025), which could tighten enforcement and reduce availability.

Conclusion

Adrafinil is a wakefulness-promoting compound that works only after the liver turns it into modafinil. For health-focused adults weighing it as a tool for alertness and focus, nearly everything known about its effects in people is borrowed from modafinil research rather than measured with adrafinil itself, and the original French studies in older adults are small, hard to access and decades old.

Through modafinil, the most consistent effect is on staying alert and performing during sleep loss. Gains in rested, healthy people are small and limited to certain tasks, and the mood benefits apply to people already being treated for depression. The idea that it supports the aging brain rests mainly on dog studies run by researchers tied to a veterinary company that patented this use, much of the modafinil research was paid for by the drug’s maker, and the early animal work on adrafinil came from its own manufacturer’s laboratory.

The main concerns are poor sleep when taken late, headache and nervousness, higher blood pressure, rare but serious skin reactions, mental-health reactions in vulnerable people, some potential for misuse, less reliable hormonal contraception, and an unmeasured load on the liver. Because adrafinil is now sold only through unregulated channels, what a capsule actually contains adds its own uncertainty.

Overall, adrafinil rests on a thin and indirect evidence base: a plausible short-term alertness tool whose long-term safety has never been directly studied in people.

Top - Benefits - Risks - Protocol